Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a bright lamp lift teen depression? new study tests home light therapy

NCT ID NCT06913309

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether using a bright light device at home for 40 minutes each morning can help teens aged 13-17 with major depression. Participants are split into three groups: high-intensity light, medium-intensity light, or a dim red light placebo. The goal is to see if light therapy safely reduces depressive symptoms and improves sleep, thinking, and mood over four weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
bright light therapy (device)
What this could lead to
If it works, this could offer a safe, non-drug option to ease depression symptoms in teens, possibly improving mood and daily function.
What could go wrong
This is an early-stage trial with only 168 participants, so results may not apply to all teens. The placebo effect from light exposure could also blur the true benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 168 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2025

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

13 to 17 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

The inclusion and exclusion criteria for MDD patients: 1. inclusion criteria * Meeting DSM-IV diagnostic criteria for a major depressive episode (first-episode or recurrent) , confirmed by two experienced, independent psychiatrists using the Mini International Neuropsychiatric Interview for Children and Adolescents (MINI-Kid); * Aged 13-17 years ; * Medication-naïve or on a stable pharmacological regimen for ≥1 week prior to enrollment; * Baseline Hamilton Depression Rating Scale-17 (HAMD-17) score ≥14; * Minimum of 5 years of formal education, with the ability to complete clinical assessments and comprehend study-related information; * Voluntary participation with written informed consent provided by both participants and their legal guardians. 2. exclusion criteria * Current or past diagnosis of psychiatric disorders other than anxiety or sleep disorders; * History of substance abuse or dependence history (including alcohol, nicotine, or illicit drugs); * Baseline Young Mania Rating Scale (YMRS) total score ≥6; * Received or planned to initiate non-pharmacological systemic interventions within 6 months prior to enrollment or within 1 month after enrollment, including but not limited to: structured psychotherapy (≥1 session/month for \>6 months), physical therapy (e.g., modified electroconvulsive therapy \[MECT\], repetitive transcranial magnetic stimulation \[rTMS\], transcranial direct current stimulation \[tDCS\], or deep brain stimulation \[DBS\]), or exercise therapy ; * Clinician-assessed suicide risk or a HAMD-17 item 3 score ≥3 at the baseline; * Presence of severe systemic or neurological conditions, such as diabetes, hypertension, renal failure, hepatic dysfunction, thyroid disorders, encephalitis, traumatic brain injury, or epilepsy; * Severe retinal pathologies (e.g., retinal detachment, optic atrophy, macular degeneration); or having high myopia (spherical equivalent ≤ -6.00 diopters); * Current use of photosensitizing agents or medications (e.g., chlorpromazine, hypericum extract); * Any other condition deemed inappropriate by the investigators(e.g., cases involving severe sleep phase delays that make morning therapy impossible, or unrecorded photosensitivity). The inclusion and exclusion criteria for Health controls 1. Inclusion criteria * Aged 13-17 years and right-handed; * Minimum of 5 years of formal education, with the ability to complete clinical assessments and comprehend study-related information; * Voluntary participation with written informed consent provided by both participants and their legal guardians. 2. Exclusion criteria * Current or lifetime diagnosis of any psychiatric disorders (e.g., schizophrenia, mood disorders, anxiety disorders) or history of substance/drug abuse or dependence; * First-degree family history of psychiatric disorders; * Presence of severe systemic or neurological disorders, such as diabetes, hypertension, renal failure, hepatic dysfunction, thyroid disorders, encephalitis, traumatic brain injury, or epilepsy; * Any other condition deemed inappropriate by the investigators.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Depressive disorder, major are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Beijing Huilongguan Hospital

    RECRUITING

    Beijing, Beijing Municipality, 10000, China

  • Peking University Sixth Hospital

    RECRUITING

    Beijing, Beijing Municipality, 10000, China

  • Yan'an Third People's Hospital

    RECRUITING

    Yanan, Shanxi, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.